Merck

Merck (U.S.) (MRK) Q4 2025 Earnings Call Transcript

Merck (U.S.) (MRK) Q4 2025 Earnings Call Transcript

By
February 3, 2026
Merck (U.S.) (MRK) Q3 2025 Earnings Call Transcript

Merck (U.S.) (MRK) Q3 2025 Earnings Call Transcript

By
October 30, 2025
Merck (U.S.) (MRK) Q2 2025 Earnings Call Transcript

Merck (U.S.) (MRK) Q2 2025 Earnings Call Transcript

By
July 29, 2025
Merck exec says Chernobyl changed the course of her life after her father begged her to leave nuclear physics on his deathbed
Success

Merck exec says Chernobyl changed the course of her life after her father begged her to leave nuclear physics on his deathbed

By
June 17, 2025
Queens of influence: Meet the women shaping Europe’s future
Conferences

Queens of influence: Meet the women shaping Europe’s future

By
May 23, 2025
Pharma giant Merck expects Trump’s tariffs to cost the company $200 million
Health

Pharma giant Merck expects Trump’s tariffs to cost the company $200 million

By Maia Anderson and Healthcare Brew
April 25, 2025
Merck (U.S.) (MRK) Q1 2025 Earnings Call Transcript

Merck (U.S.) (MRK) Q1 2025 Earnings Call Transcript

By
April 24, 2025
Cancer vaccination, conceptual illustration
Health

Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows

By
February 7, 2025
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Commentary

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

By Jeffrey Sonnenfeld and Steven Tian
February 5, 2025
Close-up of cast metal sign for the pharmaceutical company Merck
Health

Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential

By
February 4, 2025
Merck (U.S.) (MRK) Q4 2024 Earnings Call Transcript

Merck (U.S.) (MRK) Q4 2024 Earnings Call Transcript

By
February 4, 2025
A nurse administers a dose of the HPV vaccine at an Illinois health clinic in 2018.
Health

Merck’s $8 billion cancer vaccine faces first U.S. jury trial

By Bloomberg and Peter Blumberg
January 27, 2025
Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.
Health

Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows

By
December 20, 2024
Merck snags Chinese obesity drug in nearly $2 billion deal
Tech

Merck snags Chinese obesity drug in nearly $2 billion deal

By Robert Langreth and Bloomberg
December 19, 2024
Just 25% of people at high risk of pneumococcal disease—children younger than 2, adults older than 64, and those with certain chronic health conditions such as diabetes—have been immunized, according to an August 2024 survey by the National Foundation for Infectious Diseases.
Health

Pneumonia can be a deadly complication of COVID, the flu, and RSV: What to know about pneumococcal vaccination

By
October 22, 2024

Most Popular